Cartalax (20mg)

Cartalax (20mg): Ala-Glu-Asp (AED) Tripeptide — A Khavinson Cartilage and Joint-Tissue-Specific Short Peptide Bioregulator (Cytogen) with a Molecular Weight of Approximately 333 Daltons, Whose Amino Acid Sequence Corresponds to a Motif Found in the Alpha-1 Chain of Type XI Collagen (a Structural Protein Critical for Cartilage Integrity), Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, Proposed to Enter Chondrocytes and Fibroblasts via Peptide Transporters (POT and LAT Families), Penetrate to the Nucleus, Bind Complementarily to DNA Regulatory Regions and Histone Proteins, Decondense Heterochromatin, Reactivate Age-Silenced Cartilage-Specific Genes (Including COL2A1 Encoding Type II Collagen — the Predominant Structural Collagen of Articular Cartilage, and ACAN Encoding Aggrecan — the Principal Proteoglycan Responsible for Cartilage Compressive Resistance), Modulate Chondrocyte Proliferation and Differentiation, Reduce Chondrocyte Apoptosis and Senescence (via Reduction of Caspase Activation and p53-Linked Signaling), Exert Anti-Inflammatory Effects by Suppressing Catabolic Cytokines in Cartilage Tissue, and Regulate Matrix-Remodeling Enzymes — With Preclinical In Vitro Evidence from Russian Research Groups Suggesting Chondroprotective Effects in Osteoarthritis Models, but No Independent Western Validation, No Animal Model Validation for Osteoarthritis, and No Human Clinical Trials of Any Kind

Cartalax is a synthetic tripeptide bioregulator with the amino acid sequence Ala-Glu-Asp (abbreviated AED, using single-letter amino acid codes: A = alanine, E = glutamic acid, D = aspartic acid), developed by Professor Vladimir Khavinson and his research group at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, as part of their extensive research program on short peptide bioregulators (also called cytomedines or cytogens) — a class of very short peptides (typically 2-4 amino acids) proposed to act as tissue-specific signaling molecules that penetrate cell membranes, enter the nucleus, interact with DNA and histone proteins, and modulate gene expression to restore normal cellular function and reverse age-related dysregulation in the target organ. Cartalax is the cartilage and joint-tissue-specific member of this family, designed to interact preferentially with chondrocytes (the specialized cells responsible for producing and maintaining the cartilage extracellular matrix) and fibroblasts (the connective tissue cells that produce collagen and other extracellular matrix components in tendons, ligaments, and joint capsules), supporting cartilage maintenance, joint health, and connective tissue repair. With a molecular weight of approximately 333 Daltons, Cartalax is one of the smallest bioregulator peptides in the Khavinson series — a property that facilitates rapid systemic distribution and cellular uptake. A particularly interesting structural feature of Cartalax is that its amino acid sequence (Ala-Glu-Asp) corresponds to a motif found in the alpha-1 chain of Type XI collagen — a minor but structurally important collagen that plays a critical role in cartilage integrity by regulating the diameter and organization of Type II collagen fibrils (the predominant structural collagen of articular cartilage). This sequence homology to a cartilage-specific structural protein is consistent with the proposed tissue specificity of Cartalax for cartilage and joint tissue, and may provide a mechanistic rationale for why this particular tripeptide sequence preferentially affects cartilage-related gene expression. Cartalax is classified as a Cytogen — a laboratory-synthesized short peptide bioregulator — and is sometimes referred to by the code AED or T-31 in the research literature. It is important to note from the outset that the evidence base for Cartalax is significantly more limited than for some other Khavinson bioregulators (such as Thymalin and Epithalon, which have more extensive clinical data): all published research on Cartalax originates from Russian institutes (primarily Khavinson's group and collaborators), there is no independent Western validation, the entire published record is preclinical (in vitro tissue culture and limited rodent studies), there are no osteoarthritis animal model studies (despite osteoarthritis being the primary proposed indication), and there are absolutely no human clinical trials of any kind. This very limited evidence base must be kept firmly in mind when evaluating any claims about Cartalax's efficacy or safety^{[1][2][3][4][5][6][7][8][9][10]}.

Mechanism of Action: Peptide Transporter Uptake, Nuclear DNA/Histone Binding, Cartilage-Specific Gene Reactivation, and Chondroprotective Effects

The proposed mechanism of action of Cartalax — like other Khavinson peptide bioregulators — is fundamentally epigenetic and gene-regulatory, rather than receptor-mediated or enzymatic. Unlike most conventional drugs, peptide hormones, and growth factors that act by binding to specific cell-surface receptors (G protein-coupled receptors, receptor tyrosine kinases, cytokine receptors, etc.) and triggering intracellular signaling cascades, Cartalax is proposed to act directly at the level of chromatin structure and gene expression — entering chondrocytes and fibroblasts, penetrating to the nucleus, binding complementarily to specific DNA sequences in gene promoter regions and to histone proteins, and modifying the epigenetic landscape to restore more youthful patterns of cartilage-specific gene expression. The proposed mechanism involves the following key steps and effects^{[1][2][3][4][5][6][7][8]}:

• Step 1 — Systemic distribution and cellular uptake via peptide transporters (POT and LAT families): After administration (typically by subcutaneous or intramuscular injection, though some Khavinson peptides are also available as oral/nasal formulations), Cartalax — being a very small tripeptide (~333 Da) — is rapidly absorbed and distributed systemically. Unlike larger peptides and proteins that may have difficulty crossing cell membranes, short peptides like Cartalax are proposed to enter cells through specific peptide transporter systems, particularly the POT (Proton-coupled Oligopeptide Transporter) family (including PEPT1/SLC15A1 and PEPT2/SLC15A2, which transport di- and tripeptides across cell membranes using a proton gradient) and the LAT (L-type Amino acid Transporter) family (including LAT1/SLC7A5 and LAT2/SLC7A8, which transport large neutral amino acids and some short peptides). These transporter-mediated uptake mechanisms provide a biologically plausible route for Cartalax to enter chondrocytes and fibroblasts, even though cartilage is an avascular tissue (nutrients and molecules reach chondrocytes through diffusion from the synovial fluid and subchondral bone vasculature — and Cartalax's small size facilitates this diffusion). Once inside the cell, the tripeptide is small enough to passively diffuse through nuclear pore complexes (which allow passage of molecules smaller than ~40-60 kDa, so a 333 Da peptide easily passes) to enter the nucleus, where it can interact with nuclear and chromatin structures^{[1][2][3][4][7]}.
• Step 2 — Complementary DNA and histone binding — chromatin remodeling and heterochromatin decondensation: The central mechanistic step is the proposed complementary binding of Cartalax (AED) to specific DNA sequences in gene promoter regions and to histone proteins, leading to chromatin remodeling — specifically, the decondensation of heterochromatin (the tightly packed, transcriptionally silent form of chromatin). According to the Khavinson theory, short peptides bind complementarily to specific DNA sequences in the promoter regions of tissue-specific genes — with the peptide's amino acid sequence determining which DNA sequences it recognizes and binds to, through complementary charge interactions and hydrogen bonding between the peptide's amino acid side chains and the DNA's nucleotide bases. For Cartalax (AED), the proposed targets include genes involved in proteoglycan synthesis, collagen production, and chondrocyte proliferation — the molecular machinery of cartilage maintenance. Cartalax also binds to histone proteins, modifying their post-translational modification state (such as increasing histone acetylation — associated with euchromatin and transcriptional activation, because acetylation neutralizes the positive charge of histone tails, reducing their affinity for negatively charged DNA and loosening chromatin compaction; or reducing histone methylation marks associated with heterochromatin, such as H3K9me3 or H3K27me3). The net effect of these DNA and histone interactions is the decondensation of heterochromatin — converting the tightly packed, transcriptionally silent DNA back into open, accessible, transcriptionally active euchromatin — which restores transcriptional access to age-silenced cartilage-specific genes, allowing them to be re-expressed. This proposed mechanism is consistent with the broader Khavinson theory of peptide bioregulation, but it is important to note that the specific DNA binding sequences, binding affinities, and genome-wide binding patterns of Cartalax (and indeed all Khavinson short peptides) have not been fully characterized by high-resolution structural biology techniques (such as X-ray crystallography of peptide-DNA complexes, NMR spectroscopy, or ChIP-seq to demonstrate genome-wide binding patterns) in mainstream molecular biology — so the mechanism remains a working hypothesis with significant mechanistic uncertainty^{[1][2][3][4][5][6][7][8]}.
• Step 3 — Reactivation of cartilage-specific genes (COL2A1, ACAN, and others): As a consequence of chromatin decondensation and gene reactivation, Cartalax is proposed to upregulate the expression of several key cartilage-specific genes, including: (a) COL2A1 — the gene encoding Type II collagen, which is the predominant structural collagen of articular cartilage (comprising approximately 90-95% of the collagen in hyaline cartilage) and is responsible for providing tensile strength and structural framework to the cartilage matrix; reduced Type II collagen synthesis is a hallmark of cartilage degeneration in osteoarthritis; (b) ACAN — the gene encoding aggrecan, which is the principal proteoglycan in articular cartilage, responsible for providing compressive resistance and water retention (aggrecan molecules are highly negatively charged due to their glycosaminoglycan side chains, attracting water ions and giving cartilage its shock-absorbing properties); aggrecan loss is one of the earliest and most significant changes in osteoarthritis; (c) other cartilage-specific extracellular matrix components, including other collagen types (Type IX and Type XI collagen, which are minor collagens that regulate fibril diameter and organization), proteoglycans (such as versican, decorin, and biglycan), and non-collagenous matrix proteins (such as cartilage oligomeric matrix protein [COMP], matrilins, and chondroadherin); and (d) genes involved in chondrocyte proliferation, differentiation, and survival. By reactivating the expression of these cartilage-specific genes, Cartalax is proposed to restore the synthetic capacity of chondrocytes — which becomes impaired with aging and in osteoarthritis (where chondrocytes shift from a synthetic, matrix-producing phenotype to a catabolic, matrix-degrading phenotype, producing inflammatory cytokines and matrix-degrading enzymes instead of healthy matrix components)^{[1][2][3][4][5][6][7][8]}.
• Step 4 — Chondrocyte proliferation, differentiation, and anti-apoptotic/anti-senescence effects: In addition to promoting matrix synthesis, Cartalax is proposed to have direct effects on chondrocyte behavior, including: (a) stimulation of chondrocyte proliferation — increasing the number of chondrocytes in the cartilage tissue, which is important because chondrocyte density decreases with aging and in osteoarthritis (chondrocyte loss is a key feature of cartilage degeneration); (b) promotion of chondrocyte differentiation — maintaining the differentiated, matrix-producing phenotype of chondrocytes (rather than allowing them to dedifferentiate into a fibroblast-like phenotype, which occurs in osteoarthritis and leads to production of inappropriate matrix components such as Type I collagen instead of Type II collagen); (c) anti-apoptotic / cell survival effects — AED reportedly reduces markers of cell-stress and apoptosis (including caspase activation and p53-linked signaling) in chondrocytes subjected to oxidative or mechanical stress in culture; this is significant because increased chondrocyte apoptosis (programmed cell death) is a major contributor to chondrocyte loss in osteoarthritis, and reducing apoptosis could help preserve chondrocyte density and function; and (d) anti-senescence effects — Cartalax is proposed to reduce senescence markers in chondrocytes (cellular senescence is a state of irreversible cell cycle arrest associated with aging and tissue degeneration, and senescent chondrocytes accumulate in osteoarthritic cartilage and produce a pro-inflammatory, catabolic "senescence-associated secretory phenotype" [SASP] that drives cartilage degeneration); by reducing chondrocyte senescence, Cartalax could help maintain a healthier, more functional chondrocyte population^{[1][2][3][4][5][6][7][8]}.
• Step 5 — Anti-inflammatory effects and regulation of matrix-remodeling enzymes: Cartalax is proposed to exert anti-inflammatory effects in cartilage tissue by suppressing catabolic cytokines and inflammatory mediators, including: (a) suppression of pro-inflammatory cytokines — reducing the production and activity of catabolic cytokines such as interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), which are key drivers of cartilage degeneration in osteoarthritis (these cytokines stimulate chondrocytes to produce matrix-degrading enzymes and suppress matrix synthesis, creating a vicious cycle of cartilage destruction); (b) regulation of matrix-remodeling enzymes — modulating the expression and activity of matrix metalloproteinases (MMPs, particularly MMP-1, MMP-3, MMP-9, and MMP-13, which are responsible for degrading collagen and proteoglycans in cartilage) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family enzymes (particularly ADAMTS-4 and ADAMTS-5, which are the primary aggrecan-degrading enzymes in osteoarthritis); by regulating these enzymes, Cartalax is proposed to shift the balance from matrix degradation (catabolism) toward matrix synthesis (anabolism), helping to preserve and potentially restore cartilage matrix; and (c) reduction of oxidative stress — Cartalax may reduce oxidative stress markers in chondrocytes (oxidative stress, driven by reactive oxygen species [ROS], is a key contributor to chondrocyte damage and cartilage degeneration in osteoarthritis, particularly in the context of aging and mechanical stress). These anti-inflammatory and matrix-protective effects address multiple pathogenic mechanisms in osteoarthritis — cell loss, impaired matrix turnover, and inflammatory destruction — which is why Cartalax is proposed as a multi-target chondroprotective agent^{[1][2][3][4][5][6][7][8]}.

Comparison: Cartalax vs. BPC-157 vs. Conventional Osteoarthritis Treatments

Preclinical Evidence, Osteoarthritis Research, and Current Status

The preclinical evidence base for Cartalax is significantly more limited than for many other research peptides, and it is important to be transparent about these limitations. The entire published record on Cartalax consists of preclinical studies — primarily in vitro tissue culture experiments and a limited number of rodent studies — all originating from Russian research institutes, primarily Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology and their collaborators. There is no independent Western validation of any Cartalax findings, no osteoarthritis animal model studies (despite osteoarthritis being the primary proposed clinical indication for Cartalax), and no human clinical trials of any kind — not even small Phase I safety studies. Independent evidence aggregators such as PepCodex rate Cartalax's research evidence as "Very Low," with preclinical evidence at 63% and clinical evidence at 0%, based on 8 cited sources. With that important caveat, the available preclinical findings include^{[1][2][3][4][5][6][7][8][9][10]}:

In vitro chondrocyte studies (the primary evidence base): The majority of Cartalax research consists of in vitro experiments using cultured chondrocytes (cartilage cells), typically isolated from animal sources (rat, bovine, or human articular cartilage) and maintained in cell culture. Key findings from these studies include: (a) stimulation of chondrocyte proliferation — Cartalax (AED) treatment reportedly increases chondrocyte proliferation rates in culture, suggesting a direct mitogenic effect on cartilage cells; (b) increased Type II collagen synthesis — studies report increased expression of COL2A1 (the gene encoding Type II collagen) and increased Type II collagen protein synthesis in Cartalax-treated chondrocytes, as measured by gene expression assays (qPCR, microarray) and protein detection (immunohistochemistry, Western blot, ELISA); (c) increased aggrecan production — Cartalax treatment reportedly increases aggrecan (ACAN) gene expression and proteoglycan synthesis in chondrocytes, as measured by proteoglycan staining (Alcian blue, Safranin O) and biochemical assays; (d) anti-apoptotic effects — AED reportedly reduces markers of cell-stress and apoptosis (including caspase activation, DNA fragmentation, and p53-linked signaling) in chondrocytes subjected to oxidative stress (e.g., hydrogen peroxide exposure) or mechanical stress (e.g., cyclic compression) in culture, suggesting a cytoprotective effect under stress conditions; (e) anti-senescence effects — some studies report reduced senescence markers (such as senescence-associated beta-galactosidase [SA-β-gal] staining and p16INK4a expression) in aged or stressed chondrocytes treated with Cartalax; (f) anti-inflammatory effects — Cartalax reportedly suppresses the production of catabolic and pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) in chondrocytes stimulated with inflammatory mediators, and may reduce the expression of matrix-degrading enzymes (MMPs, ADAMTS); and (g) gene expression profiling — microarray and qPCR studies have examined the effects of Cartalax on global gene expression in chondrocytes, reporting modulation of genes involved in extracellular matrix synthesis, cell proliferation, apoptosis, inflammation, and cellular metabolism — though the specific gene sets and magnitude of changes vary between studies. While these in vitro findings are consistent with the proposed chondroprotective mechanism, it is critical to note that in vitro tissue culture findings do not necessarily predict in vivo efficacy — chondrocytes in culture behave very differently from chondrocytes in intact cartilage (they are removed from their normal three-dimensional matrix environment, mechanical loading conditions, and systemic hormonal/inflammatory context), and many compounds that show promising effects in vitro fail to demonstrate efficacy in animal models or human trials^{[1][2][3][4][5][6][7][8]}.

Limited rodent studies: There are a limited number of in vivo rodent studies examining Cartalax's effects, though these are far fewer and less detailed than the in vitro studies, and none (to our knowledge) have used standard osteoarthritis animal models (such as the destabilization of the medial meniscus [DMM] model, the anterior cruciate ligament transection [ACLT] model, or the collagenase-induced OA model — which are the gold standard preclinical models for testing osteoarthritis therapies). The available rodent studies have primarily examined Cartalax's effects on general aging parameters, connective tissue homeostasis, and gene expression in various tissues, rather than specifically testing cartilage protection in osteoarthritis models. These studies have reported findings consistent with the Khavinson theory of peptide bioregulation — including modulation of gene expression, reduction of age-related markers, and potential connective tissue protective effects — but they are limited in number, scope, and methodological rigor, and have not been independently replicated. The absence of osteoarthritis animal model studies is a particularly significant gap, given that osteoarthritis is the primary proposed clinical indication for Cartalax — without demonstrating efficacy in well-validated OA animal models (which include histological assessment of cartilage damage, measurement of cartilage thickness and proteoglycan content, behavioral assessment of pain and function, and molecular analysis of cartilage markers), it is impossible to determine whether Cartalax's promising in vitro effects translate to meaningful chondroprotection in a living organism with intact joint mechanics and systemic physiology^{[1][2][3][4][5][6][7][8][9][10]}.

Mechanistic skepticism and pharmacological challenges: The proposed mechanism of Cartalax — like all Khavinson short peptide bioregulators — faces several significant pharmacological and mechanistic challenges that have been raised by skeptical observers and that have not been adequately addressed in the published literature: (a) tissue specificity without receptors — unlike conventional drugs that achieve tissue specificity through selective receptor expression, Khavinson peptides are proposed to achieve tissue specificity through complementary DNA sequence binding — but it is unclear how a 3-amino-acid peptide can achieve sufficient DNA sequence specificity to selectively regulate cartilage-specific genes while not affecting genes in other tissues, given that short peptides have limited binding surface and the human genome contains millions of potential binding sites; (b) binding affinity and specificity — the actual binding affinity and specificity of Cartalax (or any Khavinson short peptide) for specific DNA sequences have not been measured using standard biochemical techniques (such as electrophoretic mobility shift assays [EMSA], surface plasmon resonance [SPR], or isothermal titration calorimetry [ITC]), so it is unknown whether these peptides actually bind DNA with sufficient affinity and specificity to produce meaningful gene regulatory effects at physiological concentrations; (c) in vivo bioavailability and stability — short peptides are generally susceptible to degradation by proteases and peptidases in the bloodstream and tissues, and it is unclear whether Cartalax, when administered systemically, reaches chondrocytes in the avascular cartilage at concentrations sufficient to produce the observed in vitro effects — cartilage is an avascular tissue with limited molecular penetration, particularly for peptides (even small ones), and the synovial fluid and cartilage matrix present significant diffusion barriers; (d) nuclear entry and chromatin access — while Cartalax is small enough to passively diffuse through nuclear pores, it is unclear whether it can actually access the specific heterochromatin regions it is proposed to decondense, given that heterochromatin is highly compacted and may be physically inaccessible to small molecules; and (e) lack of high-resolution structural evidence — the proposed peptide-DNA and peptide-histone interactions have not been visualized or characterized at atomic resolution using X-ray crystallography, cryo-EM, or NMR, which are the standard techniques for demonstrating molecular interactions in mainstream structural biology. These mechanistic uncertainties do not disprove the Khavinson theory, but they do mean that the proposed mechanism remains a working hypothesis rather than an established pharmacological principle, and that the in vitro findings could potentially be explained by alternative mechanisms (such as non-specific charge effects, modulation of cell culture conditions, or off-target effects) rather than the specific gene-regulatory mechanism proposed by Khavinson^{[1][2][3][5][6][7][8][10]}.

Current status, regulatory considerations, and important caveats: As of 2026, Cartalax remains an investigational research peptide with no approved clinical indications anywhere in the world. It is NOT FDA-approved for any indication in the United States, and it is not approved as a prescription medication in most Western countries. It is classified as a research chemical/investigational peptide, and is sold by numerous online peptide vendors primarily for laboratory research use. The sale of Cartalax for human consumption (as opposed to laboratory research use) may violate FDA regulations, particularly if the product is marketed for human therapeutic use or for the treatment of osteoarthritis, joint pain, or other medical conditions. Individuals should be aware of and comply with their local laws and regulations regarding research peptides and investigational compounds. Several important caveats must be emphasized: (1) no human clinical trials — there are absolutely no human clinical trials of Cartalax for any indication, so its safety, tolerability, pharmacokinetics, optimal dosing, and efficacy in humans are completely unknown; (2) no osteoarthritis animal models — despite osteoarthritis being the primary proposed indication, there are no studies testing Cartalax in well-validated OA animal models, so its chondroprotective efficacy in vivo is unproven; (3) single-nation, single-group evidence — all published research originates from Russian institutes, primarily Khavinson's group, with no independent Western replication; (4) mechanistic uncertainty — the proposed DNA/histone binding mechanism has not been confirmed by high-resolution structural biology, and faces significant pharmacological challenges; (5) theoretical tumor-promoting concern — because Cartalax is proposed to stimulate chondrocyte proliferation and reactivate gene expression, there is a theoretical concern that it could promote the growth of cartilage tumors (chondrosarcomas) or other cancers — this has NOT been demonstrated, and no long-term carcinogenicity studies have been conducted, but it is a biologically plausible concern that warrants investigation, particularly given that Cartalax promotes cell proliferation (a hallmark of cancer); (6) unknown long-term safety — the long-term safety of Cartalax in humans has not been established, and animal studies (where they exist) are too limited in duration and scope to detect rare or delayed adverse effects; (7) product quality variability — as a research chemical sold by numerous online vendors, the quality, purity, potency, and accuracy of labeling of Cartalax can vary dramatically between vendors, with potential for under-dosing, contamination, mislabeling, or counterfeit products; and (8) no established optimal dosing — the optimal dose, route of administration, frequency, and duration of Cartalax treatment have not been established through formal clinical trials, and vendor-recommended dosing is based on extrapolation from in vitro studies, animal data (where available), and general Khavinson peptide dosing patterns, rather than on human dose-finding studies. In summary, Cartalax represents a theoretically interesting and mechanistically novel approach to cartilage protection and osteoarthritis treatment — based on the Khavinson theory of short peptide epigenetic gene regulation, with promising in vitro findings suggesting chondroprotective effects (increased collagen and proteoglycan synthesis, reduced chondrocyte apoptosis and senescence, anti-inflammatory effects) — but it remains an experimental/investigational compound with an extremely limited evidence base (no human trials, no OA animal models, no independent Western validation), and its efficacy and safety in humans are completely unknown. Individuals with osteoarthritis or joint conditions should consult a qualified rheumatologist, orthopedist, or healthcare provider to discuss evidence-based, FDA-approved treatment options — including physical therapy, weight management, exercise, NSAIDs (with appropriate safety monitoring), corticosteroid injections (for acute flares), hyaluronic acid viscosupplementation, and in advanced cases, surgical options — rather than relying on unproven research peptides. The product offered here is injectable Cartalax (20mg vial), intended for in-vitro laboratory research use only — it is not for human or veterinary use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Peptides Clarity Research. Cartalax — compound profile. PeptidesClarity.com. 2026. (Cartalax = synthetic tripeptide bioregulator with sequence Ala-Glu-Asp [AED], developed by Prof. Vladimir Khavinson at St. Petersburg Institute of Bioregulation and Gerontology; designed to target cartilage + musculoskeletal tissue, modulating gene expression in chondrocytes + fibroblasts through epigenetic mechanisms; MW ~333 Da, one of smallest bioregulator peptides in Khavinson series)
2. Kalios Health Research. Cartalax Preclinical. Kalios.health. 2026. (Anti-apoptotic/survival: AED reportedly reduces markers of cell-stress + apoptosis [caspase activation, p53-linked signaling] in chondrocytes subjected to oxidative or mechanical stress in culture; Collagen + proteoglycan synthesis [proposed]: Khavinson model proposes increased expression of type II collagen [COL2A1], aggrecan [ACAN], + other cartilage-specific ECM components in AED-exposed chondrocytes; source data come from...)
3. PeptideInsight Research. Cartalax — osteoarthritis and cartilage degeneration. PeptideInsight.com. 2026. (Evidence level: Preclinical [in vitro]; primary research application = cartilage degeneration associated with osteoarthritis; by stimulating chondrocyte proliferation + matrix production while reducing senescence markers, Cartalax addresses multiple pathogenic mechanisms in osteoarthritis: cell loss, impaired matrix turnover, inflammatory destruction; HOWEVER, these findings derive entirely from tissue culture studies and have NOT been validated in osteoarthritis animal models or human...)
4. Peptide List Research. Cartalax — sequence, origin, classification. PeptideList.org. 2026. (Cartalax = synthetic tripeptide consisting of alanine, glutamic acid, aspartic acid [Ala-Glu-Asp], developed as part of Vladimir Khavinson's bioregulator peptide system at St. Petersburg Institute of Bioregulation and Gerontology; amino acid sequence corresponds to a motif found in alpha-1 chain of type XI collagen — structural protein important for cartilage integrity; classified as a Cytogen — lab-synthesized short peptide bioregulator)
5. Peptidings Research. Cartalax — mechanism of action + mechanistic skepticism. Peptidings.com. 2026. (Proposed: Peptide-DNA Gene Regulation — Khavinson group proposes short peptides [2-4 aa] can penetrate cell membranes, enter nucleus, interact directly with DNA to regulate gene expression; for Cartalax specifically, claimed targets include genes involved in proteoglycan synthesis, collagen production, chondrocyte proliferation — molecular machinery of cartilage maintenance; The Mechanistic Skepticism: proposed mechanism faces several pharmacological challenges that have...)
6. Biomogging Research. Cartalax — AED tripeptide, transporters, mechanism. Biomogging.com. 2026. (Cartalax — Ala-Glu-Asp tripeptide, often labeled AED or T-31 — Khavinson short peptide bioregulator aimed at cartilage, tendon, connective-tissue gene expression; unlike receptor-agonist peptides, works at chromatin level: sequence penetrates cell + nuclear membranes via POT + LAT transporters, then modulates transcription of genes governing proliferation, senescence, extracellular-matrix turnover; in aging...)
7. PeptideDeck Research. Cartalax Peptide: Benefits, Dosage, Side Effects for Joint and Cartilage Repair (2026). PeptideDeck.com. 2026. (Mechanism = gene expression, not pain blocking; proposed model supported by in vitro work from Khavinson group + smaller body of Western chondrocyte studies: Cartalax enters cartilage cells [chondrocytes], reaches nucleus, binds short DNA promoter sequences governing cartilage-specific genes; downstream effects: increased collagen type II synthesis [main structural collagen of articular cartilage], increased proteoglycan production [molecules giving cartilage its...])
8. Cartalax Peptide Guide. Cartalax Peptide For Joint Recovery: Guide To Cartilage Repair, Arthritis & Injury Support. CartalaxPeptide.com. 2025. (Ultrashort bioregulator peptide Cartalax [Ala-Glu-Asp] emerged as subject of intense research for potential to address cartilage repair through highly specific gene-regulatory mechanism; unlike broad-spectrum growth factors triggering widespread signaling cascades, Cartalax hypothesized to act directly within target cell to modulate gene expression; intracellular mechanism explained in detail; focus on cartilage repair defines research direction)
9. PepCodex Research. Cartalax — evidence rating. PepCodex.com. 2026. (A synthetic tripeptide [Ala-Glu-Asp] from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair + chondrocyte function; ALL research originates from Russian institutes with NO independent Western validation or controlled human clinical trials; AED peptide · Ala-Glu-Asp · cartilage bioregulator; Research evidence: Very Low; Preclinical evidence only; Preclinical: 63%; Clinical: 0%; Based on 8 cited sources)
10. The Peptide File Research. Cartalax — evidence status. ThePeptideFile.com. 2026. (What it is: synthetic short peptide [Ala-Glu-Asp, code AED, Khavinson bioregulator series] developed at St. Petersburg Institute of Bioregulation and Gerontology; marketed in Russia as peptide bioregulator targeted at cartilage + joint tissue; Evidence: NO Human Trials — no peer-reviewed Western human clinical trial exists; entire published record is preclinical [in-vitro + rodent] with much of it sitting in Russian-language literature; Grey Peptides: Cartalax also known as Ala-Glu-Asp... Khavinson tripeptide from cartilage tissue extract — proposed to support chondrocyte function + joint tissue homeostasis in aging + osteoarthritis models; mostly pre-clinical Russian-language evidence)
11. Peptide Initiative Research. CARTALAX (Ala-Glu-Asp Tripeptide). PeptideInitiative.com. 2026. (CARTALAX = synthetic tripeptide bioregulator [Ala-Glu-Asp, AED] developed by Vladimir Khavinson + St. Petersburg Institute of Bioregulation and Gerontology; cartilage-derived peptide engineered to normalize cartilage + musculoskeletal tissue function by modulating gene expression in fibroblasts + chondrocytes; part of Khavinson peptide bioregulator series; represents breakthrough in understanding how short peptide sequences can activate tissue-specific...)
12. StackBuilder Research. Cartalax: Benefits, Evidence, Dosing & Side Effects. StackBuilder.com. 2026. (Cartalax = short-chain tripeptide [Ala-Glu-Asp-Gly — note: some sources say 4 aa, most say 3 aa AED] derived from cartilage tissue, belongs to Russian peptide bioregulator family developed by Khavinson + colleagues; tissue-specific peptide bioregulator designed to support cartilage regeneration, joint health, connective tissue repair — particular applications in osteoarthritis management + age-related cartilage degradation; unlike many supplements working through broad systemic pathways, Cartalax operates through targeted epigenetic signaling...)